Niflumic Acid-Loaded Aspasomes as a Repurposed Nanoplatform: Antitumor Effects and Modulation of PI3K/AKT/mTOR Pathway-Related Molecular Markers in Solid Ehrlich Carcinoma-Bearing Mice
Background/Objectives: Breast cancer remains a major global health challenge, with the PI3K/AKT/mTOR signaling axis playing a key role in tumor progression. Drug repurposing offers an efficient approach to cancer therapeutics. Niflumic acid (NIF), a selective cyclooxygenase-2 (COX-2) inhibitor, has demonstrated antiproliferative and pro-apoptotic effects against breast cancer cells; however, its therapeutic potential is limited by its poor solubility. This study aimed to develop, optimize, and evaluate NIF-loaded aspasomes (NIF-ASPs) against solid Ehrlich carcinoma (SEC). Methods: NIF-ASPs were optimized via a 21.41 full factorial design. The optimum (A2) formulation was evaluated for entrapment efficiency (EE%), vesicle size (VS), polydispersity index (PDI), zeta potential (ZP), and ex vivo permeation, using the skin as a model lipoidal barrier. Following intraperitoneal administration, the antitumor efficacy and associated changes in PI3K/AKT/mTOR signaling components were evaluated in SEC-bearing mice through RT-qPCR gene expression, biochemical assays, immunohistochemistry, and histopathology. Results: The optimal A2 formula exhibited an EE% of 94.83 ± 0.16%, VS of 205.55 ± 2.05 nm, PDI of 0.49 ± 0.00, ZP of −23.65 ± 0.35 mV, and about a 2.59-fold increase in skin permeation flux versus free NIF suspension. In vivo, A2 was associated with a tumor inhibition rate of 63% (NIF suspension, 51.56%). Molecular and biochemical investigations demonstrated that A2 treatment was accompanied by significant alterations in PI3K/AKT/mTOR-associated molecular markers, characterized by decreased PI3K and p-AKT levels, together with downregulation of AKT and mTOR expression. Additionally, A2 treatment resulted in significant reductions in BCL-2, p-BAD, COX-2, and MDA levels, accompanied by restoration of total antioxidant capacity and a marked increase in cleaved caspase-3 immunoreactivity. Conclusions: NIF-ASPs serve as an efficient delivery platform that significantly enhances the NIF ex vivo skin permeation and are associated with reduced tumor growth accompanied by alterations in the PI3K/AKT/mTOR pathway-related molecular markers, COX-2-related inflammation, and oxidative stress.
Authors
- Mira Magdy William (ORCID: https://orcid.org/0000-0002-0663-0893)
- Shady M. Abd El‐Halim (ORCID: https://orcid.org/0000-0002-2716-4676)
- Heba Mohammed Refat M. Selim (ORCID: https://orcid.org/0000-0001-6973-6460)
- Shaimaa Mosallam (ORCID: https://orcid.org/0009-0001-3980-719X)
- Asma B. Omer (ORCID: https://orcid.org/0000-0003-0351-3576)
- Mona Mahmoud Mostafa (ORCID: https://orcid.org/0009-0001-5908-9658)
- Mai M. El Taweel (ORCID: https://orcid.org/0000-0002-0897-7268)
- Maha Mohamed Amin (ORCID: https://orcid.org/0009-0007-1719-1797)
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- Cairo University (EG)
- October 6 University (EG)
- Almaarefa University (SA)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3390/pharmaceutics18111484
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AlMaarefa University
- Princess Nourah Bint Abdulrahman University